Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis

Adalimumab, as a TNF inhibitor biologic for the treatment of rheumatoid arthritis, is one of the top-selling drugs worldwide. As its various patents have gradually expired, experiments on its biosimilars are constantly being implemented. In this review, we summarized clinical trials of seven biosimi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, XiaoQin, Hu, Rui, Peng, Lin, Liu, MengSi, Sun, Zhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055954/
https://www.ncbi.nlm.nih.gov/pubmed/33889152
http://dx.doi.org/10.3389/fimmu.2021.638444
_version_ 1783680549500485632
author Lu, XiaoQin
Hu, Rui
Peng, Lin
Liu, MengSi
Sun, Zhen
author_facet Lu, XiaoQin
Hu, Rui
Peng, Lin
Liu, MengSi
Sun, Zhen
author_sort Lu, XiaoQin
collection PubMed
description Adalimumab, as a TNF inhibitor biologic for the treatment of rheumatoid arthritis, is one of the top-selling drugs worldwide. As its various patents have gradually expired, experiments on its biosimilars are constantly being implemented. In this review, we summarized clinical trials of seven biosimilars currently approved by the FDA and/or EMA for the treatment of rheumatoid arthritis, namely: ABP 501 (Amjevita/Amgevita/Solymbic), BI 695501 (Cyltezo), SB5 (Imraldi/Hadlima), GP2017 (Hyrimoz/Hefiya/Halimatoz), MSB11022 (Idacio), FKB327 (Hulio), and PF-06410293 (Abrilada). Overall, these biosimilars showed similar efficacy, safety, and immunogenicity to adalimumab. All biosimilar switching trials indicated that switching from adalimumab to a biosimilar does not have a significant impact on efficacy, safety, and immunogenicity.
format Online
Article
Text
id pubmed-8055954
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80559542021-04-21 Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis Lu, XiaoQin Hu, Rui Peng, Lin Liu, MengSi Sun, Zhen Front Immunol Immunology Adalimumab, as a TNF inhibitor biologic for the treatment of rheumatoid arthritis, is one of the top-selling drugs worldwide. As its various patents have gradually expired, experiments on its biosimilars are constantly being implemented. In this review, we summarized clinical trials of seven biosimilars currently approved by the FDA and/or EMA for the treatment of rheumatoid arthritis, namely: ABP 501 (Amjevita/Amgevita/Solymbic), BI 695501 (Cyltezo), SB5 (Imraldi/Hadlima), GP2017 (Hyrimoz/Hefiya/Halimatoz), MSB11022 (Idacio), FKB327 (Hulio), and PF-06410293 (Abrilada). Overall, these biosimilars showed similar efficacy, safety, and immunogenicity to adalimumab. All biosimilar switching trials indicated that switching from adalimumab to a biosimilar does not have a significant impact on efficacy, safety, and immunogenicity. Frontiers Media S.A. 2021-04-06 /pmc/articles/PMC8055954/ /pubmed/33889152 http://dx.doi.org/10.3389/fimmu.2021.638444 Text en Copyright © 2021 Lu, Hu, Peng, Liu and Sun. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Lu, XiaoQin
Hu, Rui
Peng, Lin
Liu, MengSi
Sun, Zhen
Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
title Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
title_full Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
title_fullStr Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
title_full_unstemmed Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
title_short Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
title_sort efficacy and safety of adalimumab biosimilars: current critical clinical data in rheumatoid arthritis
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055954/
https://www.ncbi.nlm.nih.gov/pubmed/33889152
http://dx.doi.org/10.3389/fimmu.2021.638444
work_keys_str_mv AT luxiaoqin efficacyandsafetyofadalimumabbiosimilarscurrentcriticalclinicaldatainrheumatoidarthritis
AT hurui efficacyandsafetyofadalimumabbiosimilarscurrentcriticalclinicaldatainrheumatoidarthritis
AT penglin efficacyandsafetyofadalimumabbiosimilarscurrentcriticalclinicaldatainrheumatoidarthritis
AT liumengsi efficacyandsafetyofadalimumabbiosimilarscurrentcriticalclinicaldatainrheumatoidarthritis
AT sunzhen efficacyandsafetyofadalimumabbiosimilarscurrentcriticalclinicaldatainrheumatoidarthritis

Ejemplares similares